Half-life in the context of medical science typically refers to the elimination half-life. The definition of elimination half-life is the length of time required for the concentration of a particular substance (typically a drug) to decrease to half of its starting dose in the body. Understanding the concept of half-life is useful for determining excretion rates as well as steady-state concentrations for any specific drug. Different drugs have different half-lives; however, they all follow this rule: after one half-life has passed, 50% of the initial drug amount is removed from the body. The characteristic decreases of drugs over time have long been studied in a field known as pharmacokinetics and are depictable by basic differential equations. Most clinically relevant drugs tend to follow first-order pharmacokinetics; that is, their drug-elimination rates are proportional to plasma concentrations. In contrast, a few drugs follow zero-order elimination in which the drug amount decreases by a constant amount over time regardless of initial concentration (i.e., ethanol). This article will focus on first-order half-life elimination as it is the most frequently encountered in clinical practice.
Half-life elimination is graphically represented with elimination curves that track the amount of a drug in the body over time, typically with time on the independent axis and drug plasma concentration on the dependent axis, as shown in Figure 1. Total drug exposure over time is represented in these graphs as the integral area under the curve (AUC). Elimination curves are useful for determining if a drug indeed follows first-order kinetics, in which case the curve should follow a logarithmic decay according to the integrated rate law of first-order reactions (Equation 1). After solving the differential equation, one can obtain the half-life equation that is commonly tested on and used in clinical practice (Equation 2). From this equation, one can quickly determine the half-life of a drug, given its predetermined rate constant k. An alternative half-life equation exists that relates half-life to other pharmacokinetic parameters known as the volume of distribution and clearance (Equation 3).
It is also worth discussing the relationship between the percentage of drug eliminated and the number of half-lives. Assuming no administration of additional drug after an initial dose, ignoring any drug-drug interactions, and assuming a physiologically healthy individual, certain quantitative constants apply to all drugs exhibiting first-order pharmacokinetics. For example, 90% of a given drug will have undergone elimination after approximately 3.3 half-lives. Even further, 94 to 97% of a drug will have been eliminated after 4 to 5 half-lives. Thus, it follows that after 4 to 5 half-lives, the plasma concentrations of a given drug will be below a clinically relevant concentration and thus will be considered eliminated. Conversely, the accumulation of a drug can reach a steady-state during an infusion. When administering a drug at regular intervals or a constant amount (such as an infusion), the drug achieves a given steady-state concentration after approximately 4 to 5 half-lives without any further accumulation in the body with repeated doses. This state is because the infusion rate and the clearance of the drug will have reached an equilibrium, and thus the net concentration of drug in the body will remain constant. The value of this steady-state concentration is determined by the dosage, dosing interval, and clearance.
Half-life is one of the oldest pharmacokinetic parameters discussed in the medical community yet continues to be a source of confusion for many medical students and even well-versed clinicians. For this reason, the USMLE examiners continue to evaluate medical students and licensed physicians on this elusive topic. Within the concept of half-life, many assumptions are necessary, including a one-compartment system metabolizing the drug, a perfectly first-ordered system free of any renal or hepatic deficiencies, and an isolated system without any drug-drug interactions or alternative metabolic pathways. This situation is seldom the case in a clinical setting where physicians have patients who present with chronic kidney disease or other ailments, and who may take numerous medications with potential drug interactions. Also, patient age is a significant factor in determining the accurate half-life of a drug, particularly for pediatric and geriatric patients in which drug metabolism and thus half-life can vary significantly from a healthy middle-aged adult. Because of the highly theoretical model of half-life, it is often challenging to implement into practice and use it as a tool for clinical decision making. Thus, medical students and physicians need to factor such realities into half-life calculations for effective and safe pharmacological management. Numerous studies have attempted to establish methodologies that account for such nuances in the management of disease based on individual pharmacokinetic drug profiles.
The clinical significance of half-life tends to arise in situations involving drug toxicity. These incidences can result from patients who have overdosed or received an incorrect amount of a particular drug from medical staff, who have clinically significant renal or hepatic failure, or who have any other multitude of factors that increase drug plasma concentrations above a given toxic threshold. In the case of renal failure, drug excretion will be impaired, and consequently, the peak initial concentration and excretion rate of a given drug will increase. Hepatic disease also affects the half-life of a given drug due to impaired metabolism. Because the liver inactivates active metabolites at a slower rate, the body will take a more extended period to remove the drug from circulation. Half-life is also clinically relevant when physicians must determine the most efficient yet safest dosing schedule to achieve an optimal therapeutic effect, or when a steady-state concentration of a drug is desirable. The regular occurrence of these types of clinical scenarios explains why medical professionals rely so frequently on half-life drug calculations in practice, and why it continues to receive emphasis throughout medical education.
Understanding the concept of half-life when establishing dosing schedules is an important first step in the pharmacological treatment of a patient. Arguably more important, though, is the communication of this management plan from physician or pharmacist to the interprofessional care team. Effective communication continues to be a significant determinant of quality care delivery. One literature review suggests that communication requires heavy emphasis before entering clinical settings so that healthcare professionals during training can have an adequate mastery of these skills by the time they have patient interactions. Interestingly, face-to-face communication was considered the most effective modality for understanding a patient's care plan completely, yet written modalities continued to be the most commonly utilized. This is not to say, however, that written communication does not go without its strengths. Written communication provides a more permanent record that can be revisited if needed. Also, the evolution of electronic medical records allows for almost instantaneous transmission of entire patient records regardless of the distance between healthcare providers, something that face-to-face communication is less suited for [Level 4].
Unsurprisingly, interprofessional communication has been correlated with patient satisfaction, as well. Conversely, poor communication has been a cited issue in more than 80% of lawsuits, which only further highlights how imperative effective communication is in the healthcare field. This poor communication could have occurred during any point throughout a patient's care, whether it was between patient to staff member, nurse to physician, between physicians, or physician to the patient. Due to the complexity of any individual's course through the healthcare system, From a financial perspective, Medicare continues to utilize patient satisfaction surveys in determining hospital reimbursement through pay-for-performance programs, which have proven to be an effective incentive for healthcare professionals and how they conduct themselves with and around patients. Countless studies similar to those mentioned previously support the push for improving communication techniques. This aspect of healthcare continues to be heavily researched because of its implications in patient satisfaction with healthcare professionals and remains a top priority for hospitals and healthcare providers worldwide.
|||Borowy CS,Ashurst JV, Physiology, Zero and First Order Kinetics 2019 Jan; [PubMed PMID: 29763041]|
|||Erkent U,Koytchev R, The use of truncated area under the curves in the bioequivalence evaluation of long half-life drugs. Studies with donepezil and memantine. Arzneimittel-Forschung. 2008; [PubMed PMID: 18589560]|
|||Oie S, Drug distribution and binding. Journal of clinical pharmacology. 1986 Nov-Dec; [PubMed PMID: 3793947]|
|||Toutain PL,Bousquet-Mélou A, Plasma clearance. Journal of veterinary pharmacology and therapeutics. 2004 Dec; [PubMed PMID: 15601437]|
|||Ito S, Pharmacokinetics 101. Paediatrics [PubMed PMID: 23115489]|
|||Sahin S,Benet LZ, The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharmaceutical research. 2008 Dec; [PubMed PMID: 19015955]|
|||Gidal BE,Clark AM,Anders B,Gilliam F, The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate. Epilepsy research. 2017 Jan; [PubMed PMID: 27883934]|
|||Gorsline J,Gupta SK,Dye D,Rolf CN, Steady-state pharmacokinetics and dose relationship of nicotine delivered from Nicoderm (Nicotine Transdermal System). Journal of clinical pharmacology. 1993 Feb; [PubMed PMID: 8440766]|
|||Levy G, Pharmacokinetics in renal disease. The American journal of medicine. 1977 Apr; [PubMed PMID: 851113]|
|||Branch RA,Herbert CM,Read AE, Determinants of serum antipyrine half-lives in patients with liver disease. Gut. 1973 Jul; [PubMed PMID: 4729926]|
|||Vermeir P,Vandijck D,Degroote S,Peleman R,Verhaeghe R,Mortier E,Hallaert G,Van Daele S,Buylaert W,Vogelaers D, Communication in healthcare: a narrative review of the literature and practical recommendations. International journal of clinical practice. 2015 Nov [PubMed PMID: 26147310]|
|||Lang EV, A Better Patient Experience Through Better Communication. Journal of radiology nursing. 2012 Dec 1 [PubMed PMID: 23471099]|
|||Anhang Price R,Elliott MN,Zaslavsky AM,Hays RD,Lehrman WG,Rybowski L,Edgman-Levitan S,Cleary PD, Examining the role of patient experience surveys in measuring health care quality. Medical care research and review : MCRR. 2014 Oct [PubMed PMID: 25027409]|